Turkish Journal of Gastroenterology
Original Article

Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study

1.

Division of Gastroenterology, McGill University Health Centre, Montreal, Quebec, Canada

2.

Gastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand

3.

Division of Rheumatology, McGill University Health Centre, Montreal, Quebec, Canada

4.

Universidade Federal do Rio Grande do Sul, School of Medicine, Graduate Course Sciences in Gastroenterology and Hepatology, Porto Alegre, Brazil

5.

Department of Gastroenterology, Hungarian Defence Forces, Medical Centre, Budapest, Hungary

6.

Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary

Turk J Gastroenterol 2023; 34: 603-610
DOI: 10.5152/tjg.2023.22527
Read: 1146 Downloads: 390 Published: 10 May 2023

Background: Endoscopic healing is a key treatment target in inflammatory bowel disease; few data are available on the clinical and endoscopic efficacy of biological therapy in upper gastrointestinal Crohn’s disease. This study aimed to investigate small bowel mucosal healing and clinical efficacy of adalimumab therapy by video capsule endoscopy in patients with endoscopically active upper gastrointestinal Crohn’s disease.

Methods: This prospective, open-label, single-arm study included Crohn’s disease patients with moderate–severe endoscopic proximal small bowel involvement, defined by a Lewis score >790. Patients were treated with adalimumab monotherapy for 24 weeks. Co-primary outcomes were endoscopic healing, defined as Lewis score <350, and endoscopic response, defined as >50% decrease in Lewis score. Secondary outcomes included clinical (Harvey–Bradshaw index <4) and biomarker remission (fecal calprotectin <250 μg/g, and C-reactive protein <5 mg/L).

Results: A total of 59 Crohn’s disease patients were screened; 17 patients have met eligibility criteria and were enrolled. Endoscopic healing was observed in 8 patients (47.1%) and endoscopic response in additional 5 patients (29.4%) at 24 weeks. Median Lewis score was significantly decreased compared to baseline (1912 vs. 337, P = .0005). Eleven of 13 patients (84.6%) with clinical activity achieved clinical remission (baseline: 13/17 vs. week 24: 2/17, P < .0001). Nine of 10 patients with elevated C-reactive protein achieved normal C-reactive protein after treatment and the median C-reactive protein significantly decreased from 7.4 to 1.6 mg/L, P = .032. In contrast, no change was observed in fecal calprotectin pre- and posttreatment.

Conclusions: Adalimumab induced endoscopic healing and clinical remission in patients with active small bowel Crohn’s disease, with approximately half of the patients achieving endoscopic healing.
 

Cite this article as: Wetwittayakhlang P, Verdon C, Starr M, et al. Mucosal healing and clinical efficacy of adalimumab in small intestinal crohn’s disease (SIMCHA study): Final results from a prospective, open-label, single-arm study. Turk J Gastroenterol. 2023;34(6):603-610.

Files
EISSN 2148-5607